Silk Road Medical
Develops and manufactures less-invasive medical devices to improve the treatment of vascular disease through proprietary transcarotid therapies.
loading funding rounds…
Warburg Pincus(exited)
The Vertical Group(exited)
Janus Capital Group(exited)
Norwest Venture Partners(exited)
CRG LP(exited)
Armentum Partners(exited)
Oxford Finance(exited)
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 142 % | 83 % | 19 % | 35 % | 37 % | 28 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (95 %) | (42 %) | (56 %) | (47 %) | (36 %) | (25 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (109 %) | (83 %) | (63 %) | (49 %) | (40 %) | (31 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 30 % | 19 % | 28 % | 27 % | 26 % | 23 % | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.